AVITA Medical specializes in regenerative medicine and has an innovative device for skin restoration that treats full-thickness skin defects and vitiligo. The RECELL device uses a patient's skin cells ...

VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound ...

Please provide your email address to receive an email when new articles are posted on . More than 72% of patients were either somewhat or very satisfied with their treatment outcomes. Over 84% of ...

Please provide your email address to receive an email when new articles are posted on . Melanocyte keratinocyte transplantation can yield significant repigmentation ranging from 70% to 100%. The ...

VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced ...

The Food and Drug Administration signs off on a new wound treatment device by Avita Medical. Tech: Avita's Recell. Valencia-based Avita Medical Inc. has received FDA approval for a version of its ...

Q4 consensus $35.85M. For the quarter ended December 31, 2024, AVITA Medical (RCEL) now expects commercial revenue to be approximately $18.4M, reflecting growth of around 30% over the same period in ...

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform ...

Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases ...

As expected, no-moat Avita Medical received regulatory approval for an updated version of its current RECELL device that simplifies the user interface. The timing is no surprise, as Avita had flagged ...